|
Jun 17
|
Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress
|
|
Jun 16
|
Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note
|
|
Jun 16
|
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
|
|
Jun 16
|
2 Beaten-Down Dividend Stocks to Buy Right Now
|
|
Jun 13
|
Tariffs Create Most Patriotic Earnings Season Yet as US Firms Pander to Trump
|
|
Jun 13
|
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
|
|
Jun 12
|
BMY Reports Positive Data on Sotyktu From Arthritis Study
|
|
Jun 12
|
Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
|
|
Jun 12
|
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
|
|
Jun 11
|
Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu
|
|
Jun 11
|
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
|
|
Jun 11
|
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
|
|
Jun 11
|
Bristol Myers bolsters radiopharma portfolio with PhiloChem deal
|
|
Jun 11
|
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
|
|
Jun 10
|
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royal...
|
|
May 2
|
1 Stock Under $50 with Solid Fundamentals and 2 to Keep Off Your Radar
|
|
May 1
|
Jim Cramer Says He Likes Bristol-Myers Squibb (BMY) More Than Merck Due to Schizophrenia Drug
|
|
May 1
|
Bristol-Myers Squibb's (NYSE:BMY) Strong Earnings Are Of Good Quality
|
|
Apr 30
|
Is Bristol-Myers Squibb Company (BMY) the Best Long-Term Dividend Stock to Buy According to Billionaires?
|
|
Apr 29
|
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
|